UK Markets close in 6 hrs

Alphanate: A Sterile, Lyophilized Concentrate of FVIII (AHF) and Von Willebrand Factor - Global Drug Insight and Market Forecast 2017-2030

Research and Markets
·4-min read

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Alphanate - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Alphanate - Drug Insight and Market Forecast - 2030 report by the publisher outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Alphanate in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Alphanate, (antihemophilic factor/von Willebrand factor complex [human]), is a sterile, lyophilized concentrate of FVIII (AHF) and von Willebrand Factor (VWF). Alphanate is prepared from pooled human plasma by cryoprecipitation of FVIII, fractional solubilization, and further purification employing heparin-coupled, cross-linked agarose which has an affinity to the heparin binding domain of VWF/FVIII:C complex.

Alphanate is a combination medicine used to treat or prevent bleeding episodes in people with von Willebrand disease. Alphanate is also used to treat or prevent bleeding episodes in people with hemophilia A.Alphanate is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components. Anaphylaxis and severe hypersensitivity reactions are possible. Development of activity-neutralizing antibodies has been detected in patients receiving FVIII containing products.

Scope of the report

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.

  • Elaborated details on regulatory milestones and other development activities have been provided in this report.

  • The report also highlights the drug marketed details across the United States, Europe and Japan.

  • The report also covers the patent's information with expiry timeline around Alphanate .

  • The report contains historical and forecasted sales for Alphanate till 2030.

  • Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.

  • The report also features the SWOT analysis with analyst insights and key findings of Alphanate .

Report highlights

  • In the coming years, the market scenario for Alphanate is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

  • The companies and academics are working to assess challenges and seek opportunities that could influence Alphanate dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • Other approved products for the disease are giving market competition to Alphanate and launch of late-stage emerging therapies in the near future will significantly impact the market.

  • A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Alphanate .

  • Our in-depth analysis of the sales data of Alphanate from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Alphanate in the market.

Key Topics Covered:

1. Product Overview
1.1. Indication
1.2. Mechanism of Action
1.3. Dosage and Administration
1.4. Dosage Forms and Strengths
1.4.1 Route of Synthesis
1.5. Pharmacology
1.5.1 Pharmacodynamics
1.5.2 Pharmacokinetics
1.6. Adverse Reactions
1.7. Product Snapshot
1.8. Development Milestones of Alphanate
1.9. Marketed Details
1.9.1 United States
1.9.2 Europe
1.9.3 Japan
1.10. Patent Details

2. SWOT Analysis
2.1. Analyst Views

3. Regulatory Milestones
3.1. Approvals
3.2. Research and Development
3.3. Clinical Trials Information
3.4. Safety and Efficacy
3.5. Product Developmental Activities

4. Market Assessment
4.1. 7MM Market Analysis
4.2. United States
4.3. Europe
4.4. Japan
4.5. Key Findings

5. Market Competitors

6. Emerging Therapies

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/phwwn7

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900